Maria Rosaria De Filippo

Maria Rosaria De Filippo

Auto-generated profile, based on publicly available information

Maria Rosaria De Filippo

Department for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Epilepsy Research
Verified
Journal Article
Closed access
MFMaria Rosaria De Filippo
Maria Rosaria De Filippo
Francesca RizzoFrancesca Rizzo
Francesca Rizzo
GMGiovanna Marchese
Giovanna Marchese
GGGiorgio Giurato
Giorgio Giurato
GNGiovanni Nassa
Giovanni Nassa
Giangennaro CoppolaGiangennaro Coppola
Giangennaro Coppola

18 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SKSofia Karkampouna
Sofia Karkampouna
FMFederico La Manna
Federico La Manna
MFMaria R. De Filippo
Maria R. De Filippo
MKMirjam Kiener
Mirjam Kiener
MMMarta De Menna
Marta De Menna
MJMarianna Kruithof-De Julio
Marianna Kruithof-De Julio
Therapy resistance and metastatic processes in prostate cancer (PCa) remain undefined, due to lack of experimental models that mimic different disease stages. We describe a novel androgen-dependent PCa patient-derived xenograft (PDX) model from treatment-naïve, soft tissue metastasis (PNPCa). RNA and whole-exome sequencing of the PDX tissue and organoids confirmed transcriptomic and genomic similarity to primary tumor. PNPCa harbours BRCA2 and CHD1 somatic mutations, shows an SPOP/FOXA1 -like transcriptomic signature and microsatellite instability, which occurs in 3% of advanced PCa and has never been modelled in vivo . Comparison of the treatment-naïve PNPCa with additional metastatic PDXs (BM18, LAPC9), in a medium-throughput organoid screen of FDA-approved compounds, revealed differential drug sensitivities. Multikinase inhibitors (ponatinib, sunitinib, sorafenib) were broadly effective on all PDX- and patient-derived organoids from advanced cases with acquired resistance to standard-of-care compounds. This proof-of-principle study may provide a preclinical tool to screen drug responses to standard-of-care and newly identified, repurposed compounds.

3 February 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
FMFederico La Manna
Federico La Manna
MMMarta De Menna
Marta De Menna
NPNikhil Patel
Nikhil Patel
SKSofia Karkampouna
Sofia Karkampouna
MFMaria Rosaria De Filippo
Maria Rosaria De Filippo
MJMarianna Kruithof-de Julio
Marianna Kruithof-de Julio
Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity